Literature DB >> 25461253

C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients.

Xiaoli Wang1, Sool Yeon Cho1, Cing Siang Hu1, Daniel Chen1, John Roboz1, Ronald Hoffman2.   

Abstract

Myelofibrosis (MF) is characterized by the constitutive mobilization of hematopoietic stem cells (HSC) and hematopoietic progenitor cells (HPC) and the establishment of extramedullary hematopoiesis. The mechanisms underlying this abnormal HSC/HPC trafficking pattern remain poorly understood. We demonstrated that both splenic and peripheral blood (PB) MF CD34(+) cells equally share a defective ability to home to the marrow, but not to the spleens, of NOD/LtSz-Prkdc(scid) mice. This trafficking pattern could not be attributed to discordant expression of integrins or chemokine receptors other than the downregulation of C-X-C chemokine receptor type 4 by both PB and splenic MF CD34(+) cells. The number of both splenic MF CD34(+) cells and HPCs that migrated toward splenic MF plasma was, however, significantly greater than the number that migrated toward PB MF plasma. The concentration of the intact HSC/HPC chemoattractant C-X-C motif chemokine 12 (CXCL12) was greater in splenic MF plasma than PB MF plasma, as quantified using mass spectrometry. Functionally inactive truncated products of CXCL12, which are the product of proteolytic degradation by serine proteases, were detected at similar levels in both splenic and PB MF plasma. Treatment with an anti-CXCL12 neutralizing antibody resulted in a reduction in the degree of migration of splenic MF CD34(+) cells toward both PB and splenic MF plasma, validating the role of CXCL12 as a functional chemoattractant. Our data indicate that the MF splenic microenvironment is characterized by increased levels of intact, functional CXCL12, which contributes to the localization of MF CD34(+) cells to the spleen and the establishment of extramedullary hematopoiesis.
Copyright © 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25461253      PMCID: PMC4324010          DOI: 10.1016/j.exphem.2014.10.013

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  37 in total

1.  Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.

Authors:  G Barosi; G Viarengo; A Pecci; V Rosti; G Piaggio; M Marchetti; F Frassoni
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

2.  Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells.

Authors:  Kent W Christopherson; Giao Hangoc; Hal E Broxmeyer
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

3.  The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity.

Authors:  B Zhang; S M Lewis
Journal:  Eur J Haematol       Date:  1989-07       Impact factor: 2.997

4.  Polycythemia vera is not initiated by JAK2V617F mutation.

Authors:  Roberto H Nussenzveig; Sabina I Swierczek; Jaroslav Jelinek; Amos Gaikwad; Enli Liu; Srdan Verstovsek; Jaroslav F Prchal; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

5.  Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.

Authors:  Daniela S Krause; Katherine Lazarides; Ulrich H von Andrian; Richard A Van Etten
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

Review 6.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells.

Authors:  Tsvee Lapidot; Isabelle Petit
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

7.  Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia.

Authors:  Giovanni Barosi; Vittorio Rosti; Margherita Massa; Gian Luca Viarengo; Alessandro Pecci; Vittorio Necchi; Isabella Ramaioli; Rita Campanelli; Monia Marchetti; Mario Bazzan; Umberto Magrini
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

8.  Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.

Authors:  Marisa Parmo-Cabañas; Rubén A Bartolomé; Natalia Wright; Andrés Hidalgo; Angelika M Drager; Joaquin Teixidó
Journal:  Exp Cell Res       Date:  2004-04-01       Impact factor: 3.905

9.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4.

Authors:  Isabelle Petit; Martine Szyper-Kravitz; Arnon Nagler; Meir Lahav; Amnon Peled; Liliana Habler; Tanya Ponomaryov; Russell S Taichman; Fernando Arenzana-Seisdedos; Nobutaka Fujii; Judith Sandbank; Dov Zipori; Tsvee Lapidot
Journal:  Nat Immunol       Date:  2002-06-17       Impact factor: 25.606

10.  Transformation of polycythemia vera to acute nonlymphocytic leukemia accompanied by t(1;3)(p36;q21) karyotype.

Authors:  V Najfeld; T Coyle; P D Berk
Journal:  Cancer Genet Cytogenet       Date:  1988-07-15
View more
  15 in total

1.  SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA.

Authors:  Subbaiah Chary Nimmagadda; Stephanie Frey; Peter Müller; Denise Wolleschak; Sönke Weinert; Ulrich Keller; Bärbel Edelmann; Thomas Fischer
Journal:  Haematologica       Date:  2019-02-14       Impact factor: 9.941

2.  The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis.

Authors:  Jiajing Qiu; Mohamed E Salama; Cing Siang Hu; Yan Li; Xiaoli Wang; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-05-22

3.  Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Authors:  Christina Hart; Sabine Klatt; Johann Barop; Gunnar Müller; Roland Schelker; Ernst Holler; Elisabeth Huber; Wolfgang Herr; Jochen Grassinger
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

Review 4.  Extrinsic regulation of hematopoietic stem cells in development, homeostasis and diseases.

Authors:  Yeojin Lee; Matthew Decker; Heather Lee; Lei Ding
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2017-05-31       Impact factor: 5.814

Review 5.  Novel targets to cure primary myelofibrosis from studies on Gata1low mice.

Authors:  Maria Zingariello; Fabrizio Martelli; Paola Verachi; Claudio Bardelli; Francesca Gobbo; Maria Mazzarini; Anna Rita Migliaccio
Journal:  IUBMB Life       Date:  2019-11-21       Impact factor: 3.885

6.  Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.

Authors:  Kathryn E Cole; Quan P Ly; Michael A Hollingsworth; Jesse L Cox; James C Padussis; Jason M Foster; Luciano M Vargas; James E Talmadge
Journal:  Cell Immunol       Date:  2021-03-01       Impact factor: 4.868

7.  Bone marrow remodeling supports hematopoiesis in response to immune thrombocytopenia progression in mice.

Authors:  Oliver J Herd; Gulab Fatima Rani; James P Hewitson; Karen Hogg; Andrew P Stone; Nichola Cooper; David G Kent; Paul G Genever; Ian S Hitchcock
Journal:  Blood Adv       Date:  2021-12-14

8.  The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.

Authors:  H Zhan; C H S Lin; Y Segal; K Kaushansky
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

9.  Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-β1 and Cxcl12 pathways.

Authors:  Avik Dutta; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

10.  CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.

Authors:  Hadjer Abdelouahab; Yanyan Zhang; Monika Wittner; Shinya Oishi; Nobutaka Fujii; Rodolphe Besancenot; Isabelle Plo; Vincent Ribrag; Eric Solary; William Vainchenker; Giovanni Barosi; Fawzia Louache
Journal:  Oncotarget       Date:  2016-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.